0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ An (RCT) -38% 1.38 [1.05-1.81] hosp. 128 (n) 115 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.019 Early treatment -38% 1.38 [1.05-1.81] 128 (n) 115 (n) 38% higher risk All studies -38% 1.38 [1.05-1.81] 128 (n) 115 (n) 38% higher risk 1 GPAT COVID-19 study c19early.org May 2026 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.019 Effect extraction pre-specified(most serious outcome) Favors GPAT Favors control
Graphene photothermal adjuvant therapy (GPAT) is a device-based physical intervention that utilizes a graphene electrothermal film to deliver far-infrared radiation, investigated for its potential to modulate inflammatory immune response.
Apr 28
 An et al., Scientific Reports, doi:10.1038/s41598-026-50266-y Effects of graphene photothermal adjuvant therapy in patients infected with the Omicron BF.7 variant 2022: a prospective randomized controlled trial
38% higher hospitalization (p=0.02) and 35% worse recovery (p=0.03). RCT 243 mildly symptomatic hospitalized COVID-19 patients (Omicron BF.7 variant) in China showing increased risk with graphene photothermal adjuvant therapy (GPAT). All patients received nebulized N-acetylcysteine and the interaction with..